Dena M. Torrente

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

A. Troxel, M. Brose, M. Yarchoan, 2018 .